Anavex Life Sciences (STU:12X1) Cyclically Adjusted FCF per Share: €-0.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:12X1 Anavex Life Sciences Corp STU:12X1
37 GF Score
Price €2.42
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Cyclically Adjusted FCF per Share?

Anavex Life Sciences STU:12X1 +2.11% 37 Cyclically Adjusted FCF per Share is €-0.35 as of Jun. 2026. GuruFocus rates STU:12X1 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Anavex Life Sciences's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.085. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.35 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -7.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -5.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Anavex Life Sciences was 8.70% per year. The lowest was -7.50% per year. And the median was -1.70% per year.

As of today (2026-09-02), Anavex Life Sciences's current stock price is €2.423. Anavex Life Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.35. Anavex Life Sciences's Cyclically Adjusted Price-to-FCF of today is .


Anavex Life Sciences  (STU:12X1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Anavex Life Sciences Cyclically Adjusted FCF per Share Related Terms


Anavex Life Sciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences Cyclically Adjusted FCF per Share Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 -0.33 -0.36 -0.34 -0.33

Anavex Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.33 -0.33 -0.35 -0.35

STU:12X1 vs ALXO, TRDA, LCTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Anavex Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Cyclically Adjusted Price-to-FCF falls into.


STU:12X1
37GF Score
Anavex Life Sciences Corp STU:12X1
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anavex Life Sciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.085/333.9520*333.9520
=-0.085

Current CPI (Jun. 2026) = 333.9520.

Anavex Life Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.046 241.428 -0.064
201612 -0.078 241.432 -0.108
201703 -0.016 243.801 -0.022
201706 -0.064 244.955 -0.087
201709 -0.043 246.819 -0.058
201712 -0.070 246.524 -0.095
201803 -0.051 249.554 -0.068
201806 -0.040 251.989 -0.053
201809 -0.076 252.439 -0.101
201812 -0.079 251.233 -0.105
201903 -0.081 254.202 -0.106
201906 -0.134 256.143 -0.175
201909 -0.044 256.759 -0.057
201912 -0.094 256.974 -0.122
202003 -0.082 258.115 -0.106
202006 -0.061 257.797 -0.079
202009 -0.088 260.280 -0.113
202012 -0.101 260.474 -0.129
202103 -0.090 264.877 -0.113
202106 -0.088 271.696 -0.108
202109 -0.086 274.310 -0.105
202112 -0.041 278.802 -0.049
202203 -0.115 287.504 -0.134
202206 -0.086 296.311 -0.097
202209 -0.052 296.808 -0.059
202212 -0.070 296.797 -0.079
202303 -0.101 301.836 -0.112
202306 -0.087 305.109 -0.095
202309 -0.067 307.789 -0.073
202312 -0.082 306.746 -0.089
202403 -0.130 312.332 -0.139
202406 -0.057 314.175 -0.061
202409 -0.071 315.301 -0.075
202412 -0.136 315.605 -0.144
202503 -0.064 319.799 -0.067
202506 -0.127 322.561 -0.131
202509 -0.085 324.800 -0.087
202512 -0.069 324.054 -0.071
202603 -0.041 330.213 -0.041
202606 -0.085 333.952 -0.085

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.35 mean?
Anavex Life Sciences (STU:12X1) has a Cyclically Adjusted FCF per Share of €-0.35 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' Cyclically Adjusted FCF per Share too high?
Anavex Life Sciences' current Cyclically Adjusted FCF per Share is €-0.35. Overall, Anavex Life Sciences has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Cyclically Adjusted FCF per Share compare to ALXO and TRDA?
Anavex Life Sciences' Cyclically Adjusted FCF per Share of €-0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current Cyclically Adjusted FCF per Share is €-0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (STU:12X1) has a current Cyclically Adjusted FCF per Share of €-0.35. The current Cyclically Adjusted FCF per Share is €-0.35. Anavex Life Sciences' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Anavex Life Sciences (STU:12X1), the current Cyclically Adjusted FCF per Share is €-0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges AVXL:USA0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
37GF Score

Get the complete analysis for STU:12X1

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price